Regeneron Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 02.08.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time.Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w |
---|---|
Regeneron Pharmaceuticals Inc. | - |
iShares Core DAX® | -3.935% |
iShares Nasdaq 100 | -3.608% |
iShares Nikkei 225® | -4.513% |
iShares S&P 500 | -2.607% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
17.06.24
17.06.25
02.08.24